Press Room


    Press Release - February 16, 2012

    Sernova Announces $3.5 Million Private Placement

    $2.5M SECURED


    LONDON, ONTARIO - (Marketwire - February 16, 2012) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA) is pleased to announce a non- brokered private placement (the "Offering") of up to 19,444,444 units of the Company ("Units") at a price of $0.18 per Unit for gross proceeds of up to $3.5 million, of which $2.5 million has been secured.

    Each Unit will consist of one common share of the Company (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Share (a "Warrant Share") for a period of three years, at a price of $0.20 per Warrant Share in the first year and at a price of $0.35 per Warrant Share in the second and third years.

    "Securing these funds represents a key milestone for Sernova and a testament to continued strong investor support," stated Dr. Philip Toleikis, President and CEO. "These funds will enable Sernova to initiate the planned clinical study to investigate the safety and efficacy of the Cell Pouch(TM) in diabetic patients receiving islet cell transplantation. This study, which will be initiated in the second quarter of 2012, will represent a significant step towards a new and potentially effective treatment that would improve the quality of life in patients with diabetes."

    The Units will be made available by way of private placement exemptions in Canada under National Instrument 45-106 - Prospectus and Registration Exemptions.

    The Offering is subject to acceptance by the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of completion of the Offering, in accordance with applicable securities legislation.

    The proceeds from the Offering will be used by Sernova for research and development of its proprietary Cell Pouch System(TM) and in particular to fund the upcoming first in man clinical trial for patients with diabetes receiving an islet transplant. The funds will also be used for general and administrative expenses. This clinical trial will be conducted at the University of Alberta with Dr. James Shapiro as principal investigator. Dr. Shapiro is world renowned for advancing cutting edge technologies in the islet transplantation field and was instrumental in developing the Edmonton Protocol. The study will assess both safety and efficacy of the Cell Pouch System(TM) in up to 20 patients with unstable diabetes. In this study, patients will be implanted with Sernova's Cell Pouch(TM) and then transplanted with islets. Safety and efficacy will be monitored throughout the study.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology.

    For further information contact:

    Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

    Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251

    Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News